임상 한눈에 보기

• 1건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: Phase 1, Phase 2
• Status: Completed
• 주요 endpoint: Number of Participants With Related Treatment-emergent Adverse Event [Safety and Tolerability] (Phase 1b) · Progression-free Survival Following Treatment in Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer. · Overall Response Rate (ORR) by Tumor Marker Cancer Antigen-125 (CA-125) for Participants Enrolled in the Phase 2 Portion of Study With Platinum-resistant or Platinum-refractory Ovarian Cancer · Overall Response Rate (ORR) by RECIST 1.1 for Participants Enrolled in the Phase 2 Portion of the Study With Platinum-resistant or Platinum-refractory Ovarian Cancer
• 등록 대상자(표본 합산): 약 46명
• 선택한 코호트 보고값: ORR 80%
• 핵심: The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.